June 3, 2015 11:21pm
BLUE regains rights to CAR T Programs outside of BCMA
CELG to pay $25 M in new research funding
BLUE to independently invest in and pursue a broad T cell-Based Immuno-oncology strategy
Members only. Please login.
June 3, 2015 11:21pm
BLUE regains rights to CAR T Programs outside of BCMA
CELG to pay $25 M in new research funding
BLUE to independently invest in and pursue a broad T cell-Based Immuno-oncology strategy
Members only. Please login.
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors